Rida Mourtada is a co-founder and Chief Scientific Officer at Lytica Therapeutics, a biotechnology company focused on developing novel peptide therapeutics to treat drug-resistant bacterial infections and cancers. His passion for drug discovery led him to invent Lytica's core technologies, Stapled Antimicrobial Peptides (StAMPs) and Stapled Oncolytic Peptides (StOPs), during his graduate studies in Dr. Loren Walensky's laboratory at the Dana-Farber Cancer Institute. Rida completed his Hon. BSc. and MSc. degrees at the University of Toronto and received his doctorate from the Harvard-MIT Program in Health Sciences and Technology at MIT.